

PTO/SB/08A (10/96)
Approved for use through 10/31/99, OMB 0651-031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a yalid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	,	of	
	· ·		

Complete if Known				
Application Number				
Filing Date				
First Named Inventor	Philip G. Cavanaugh			
Group Art Unit				
Examiner Name				
Attorney Docket Number				

	U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.1	U.S. Patent I Number	Cocument Kind Code ² (# known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/J.H./		5,576,43	36	McCabe et.al.	11-01-1996	
-/J.H./		6,054,59	57	Faure	04-01-2000	·,
/J.∏./						
					 	
					1	· · · · · · · · · · · · · · · · · · ·
1		······································			* 	
				*** *	· [
•		··		· · · · · · · · · · · · · · · · · · ·	 	······································

		· · · · · · · · · · · · · · · · · · ·				
					 	
		······································		· · · · · · · · · · · · · · · · · · ·		
			 -			
					 	
		· · · · · · · · · · · · · · · · · · ·			 	

		· · · · · · · · · · · · · · · · · · ·			 	
			1 1		1	

				FORE	IGN PATENT DOCUMENT	rs		
Examiner Cite	F	oreign Patent Do	cument	Name of Patentee or	Date of Publication of	Pages, Columns, Lines,	T	
Initials*	No.1	Office ³	Number ⁴	Kind Code ⁵ (# known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Floures Appear	T®
						•]		T
						1	· · · · · · · · · · · · · · · · · · ·	1
							*	1-
								1
								1
							······································	1
								1
					•			
								


Examiner	•	Date	
Signature	/Jana Hines/	Considered	02/12/2009

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

^{*}EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See ettached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	This occupied in the fluctual 10/31/88 CMB 0651-0031
Under the Paperwork Reduction Act of 1995, on nemons are married to me	Petent and Trademark Office: U.S. DEPARTMENT OF COMMERCE pond to a collection of information unless it contains a valid OMB control number.
The persons are required to less	pond to a collection of information unless it contains a valid OMB control number
	one of realists.
Substitute for form 44 approximate	Complete H Known

Application Number	
Filing Date	
First Named Inventor	Philip G. Cavanaugh
Group Art Unit	v. vavanaugn


(use as many sheets as necessary) **Examiner Name** 2 **Attorney Docket Number**

	l l	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
		Cavanaugh, P.G. and Nicolson, G. L. "Lung derived growth factor that stimulates the growth of lung-metastasizing tumor cells: Identification as transferrin", Journal of Cellular Biochemistry, 47:261-271, 1991.	1	
		Cavanaugh, P.G., and Bicolson, G.L., "The selection of a metastatic rat mammary ademocarcinoms cell line from a low metastatic parental population by an in vitro process based on cellular ability to proliferate in response to transferrin", Journal of Cellular Physiology, 174: 48-57, 1998.	†	
		Cavanaugh, P.G., Jia, L., and Nicolson, G.L., * Transferrin receptor overexpression enhances transferrin responsiveness and the metastatic growth of a rat mammary adenocarcinoma cell line*, Breast Cancer Research and Treatment, 56:203-217, 1999.	-	
		Chaudary, S., Das, S., BanerJee, S.K., and Sarker, P.K. "Identification and characterization of a tubuline binding protein in rat brain plasma membrane", Neurochem Int, 1994, 24, 289-299.	\dagger	
		Darzynkiewicz Z, Bedner B, Traganos F, Murakami T, "Critical aspects in the analysis of apoptosis and necrosis", Hum Cell, 1998, 11,3-12.	\dagger	
		Gordon, I.L. "Scatchard analysis of fluorescent concanavalin A binding to lymphocytes", Cytometry, 1995, 20, 238-244.		
		Inoue, T., Cavanaugh., P. G., Stock, P. A., and Nicolson, G. L., "Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials", Journal of Cellular Physiology, 156: 212-217, 1993.		
		Lagrange JL, Francoual M, Formento JL, Del Guidice P, Bensadoun RJ, Teissier E, Ettore F, Gillet JY, Namer M, Milano G, "Demonstration and characterization of EGF receptors in cancer of the uterine cervix", Bull Cancer, 1993, 80, 219-224		
		Le Gall M, Chambard JC, Breittmayer JP, Grall D, Pouyssegur J, Van Obberghen-Schilling E, "The p42/p44 MAP kinase pathway prevents apoptosis induced by anchorage and serum removal", Mol Biol Cell, 2000, 11, 1103-1112.		
		Niedergang F, Alcover A, Knight CG, Farndale RW, Barnes MJ, Francischetti IM, Bon C, Leduc M, "Convulxin binding to platelet receptor GPVI: competition with collagen related peptides" Biochem Biophys Res Commun, 2000 273, 246-250.		
		Palupi NS, Franck P, Guimont C, Linden G, Dumas D, Stoltz J, Nabet P, Belleville-Nabet F, Dousset B, "Bovine beta-lactoglobulin receptors on transformed mammalian cells (hybridomas MARK-3): characterization by flow cytometry". J Biotechnol, 2000, 78, 171-184.		

Examiner			
Signature	/Jana Hines/	Date	20/10/202
Colgitatore	round i finesi	Considered	02/12/2009

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.





¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.






•	PTO/SB/08B (10-06)
Approved for use through	10/31/99. OMB 0651-0031
stent and Trademark Office: U.S. DEPA	RTMENT OF COMMERCE

Substitute for form 14498/PTO				Complete If Known		
INIEC	DMATI	241.5	1001 001100	Application Number		
INFORMATION DISCLOSURE				Filing Date		
STA	TEMEN'	ГВҮ	APPLICANT	First Named Inventor		
				Group Art Unit		
(use as many sheets as necessary)			s as necessary)	Examiner Name		
Sheet	3	of	3	Attorney Docket Number		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initiats*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
J.H	ı	Samuel D, Patt RJ, Abuknesha RA, "A sensitive method of detecting proteins on dot and Western blots using a monoclonal antibody to PITC", J Immunol Methods, 1988, 107, 217-224.	
/J.H	/	Scacchi GB, Turyn D, Dellacha JM, "Identification of insulin binding sites in isolated cells from rat submaxillary gland", Arch Biol Med Exp (Santiago), 1988, 21,189-193.	
/J.H./		Zhang G, Gurtu V, Kain SR, Yan G, "Early detection of apoptosis using a fluorescent conjugate of annexin V", Biotechniques 1997, 23,525-531.	
			-
	1		
		·	
		·	

Cumina			
Examiner	/Jana Hines/	Date	
Signature	round rimos		********
	The second secon	Considered	

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.